Physician profile
Caralee L Workman
NPI 1881443570
$1,547.08
in general payments reported to CMS, 2019-2025
22 companies · $1,547 in 2025
The $1,547 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,547.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $398.60 | 2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $205.56 | 2025 | |
| Corcept Therapeutics | $150.46 | 2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $130.18 | 2025 | |
| Dexcom, INC. | $78.46 | 2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $72.66 | 2025 | |
| Stryker Corporation | $57.75 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S, Clottriever Bold Catheter |
| Otsuka America Pharmaceutical, INC. | $52.83 | 2025 | Rexulti |
| Amgen INC. | $49.88 | 2025 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $49.69 | 2025 | Verquvo |
| Sumitomo Pharma America, INC. | $48.65 | 2025 | Gemtesa |
| Astrazeneca Pharmaceuticals LP | $43.13 | 2025 | Airsupra, Breztri |
| Abbott Laboratories | $31.19 | 2025 | |
| Medtronic, INC. | $30.29 | 2025 | Intellis Adaptivestim |
| Astellas Pharma US INC | $23.61 | 2025 | Veozah |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $23.08 | 2025 | Isturisa |
| Aimmune Therapeutics, INC. | $20.18 | 2025 | Zenpep |
| Baxter Healthcare | $18.14 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.42 | 2025 | Xifaxan |
| Esperion Therapeutics, INC. | $16.35 | 2025 | Nexletol |
| Scpharmaceuticals INC. | $14.71 | 2025 | |
| Antares Pharma, INC. | $14.26 | 2025 | Xyosted |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caralee Workman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.